Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT02565693

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02565693
  • EudraCT 2014-000112-33
  • WHO UTN U1111-1154-5474
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02565693. Randomized; single masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2021-01-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
Acronym
APACHE-AF
Condition
Cerebral Hemorrhage
Intervention (Drug)
Apixaban
Intervention (Drug)
Aspirin
Intervention (Drug)
Carbasalate calcium
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Dipyridamole
Intervention (Other)
No antithrombotic treatment
Lead sponsor
UMC Utrecht (class: other)
Collaborator
Dutch Heart Foundation (class: other)
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (class: other)

Record details

Record id
cardio:ct-nct02565693
Content hash
6270f1c994093a546ed84b51960aebec2d69ac1103c05853021ed4d949e80d07